General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press: For more information please visit our websites www.iiar-anticancer.org and www.iiarjournals.org.

Editorial Office
International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece, Tel: +30 22950 52945, Fax: +30 22950 53389
e-mail: journals@iiar-anticancer.org (Editorial Office); IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Free specimen copies of CGP are available on request.

A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HEllMAN, L. ALLDRIDGE, S. SOUCHELNYTSKYI (Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, QLD, Australia)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DUQUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (Columbia, SC; St. Louis, MO, USA)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (Munich, Germany)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, YQ. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (Norcross, GA, USA; Guangzhou, P.R. China)

TGF-β1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWE RTH, W. GOERING, R. ENGERS, W.A. SCHULZ (Düsseldorf, Germany)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDE, E. BLOMQVIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (Uppsala; Ørebro; Gävle; Karlstad; Stockholm; Sweden; Mumbai, India)

Proteomic Study from Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, K. YOSHIO, J.-I. ISHI, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU (Kanagawa, Japan)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O’MEARA, S. CRUET-HENNEQUART, M.P. CARTY (Galway, Ireland)


DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (Pomona, CA, USA)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S.E.T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA)

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRÜCK, G. PEREIRA, T. EFFERTH (Heidelberg; Mainz, Germany)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (Regensburg; Munich, Germany)
Instructions to Authors

General Policy. ANTIcancer RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Netherlands Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTIcancer RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTIcancer RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”,”epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)

2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.

3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

More Than 4 Years of Progression-free Survival in a Patient with Metastatic Renal Cell Carcinoma Treated Sequentially with Sunitinib, Everolimus, Sorafenib, and Temsirolimus. S. OUDARD (Paris, France) ...... 5223

Age Aspects of Demography, Pathology and Survival Assessment in Colorectal Cancer. K. DERWINGER, K. KODEDA, R. GERJY (Gothenburg; Linköping, Sweden) .................................................................................. 5227

Immunohistochemical Detection of Mutated Epidermal Growth Factor Receptors in Pulmonary Adenocarcinoma. H. NAKAMURA, A. MOCHIZUKI, T. SHINMYO, K. ANDO, N. KURIMOTO, K. YOKOTE, M. TAKAGI (Kawasaki, Kanagawa, Japan) .............................................................................................................. 5233

Clinical Significance of Vimentin-positive Gastric Cancer Cells. Y. FUJIHIRO, M. YASHIRO, S. NODA, S. KASHIWAGI, J. MATSUOKA, Y. DOI, Y. KATO, N. KUBO, M. OHIRA, K. HIRAKAWA (Osaka, Japan) .......................................................................................................................... 5239


KRAS Genotyping as Biomarker in Colorectal Cancer: A Comparison of Three Commercial Kits on Histologic Material. A. CAVALINI, A.M. VALENTINI, C. LIPPOLIS, D. CAMPANELLA, V. GUERRA, M.L. CARUSO (Castellana Grotte, Italy) .................................................................................................................. 5251

Association Between EGF, TGF-β1, TNF-α Gene Polymorphisms and Cancer of the Pancreatic Head. G.-Y. WU, Q. LU, T. HASENBERG, M. NIEDERGETHMANN, S. POST, J.W. STURM, M. KEESE (Xiamen, PR China; Mannheim, Germany) .............................................................................................................. 5257

Book Reviews .......................................................................................................................................................................................... 5263

Announcements .................................................................................................................................................................................. 5267

Errata .......................................................................................................................................................................................................................... 5269


Dopamine Excess in Patients with Head and Neck Paragangliomas. A.N.A. VAN DER HORST-SCHRIVERS, T. E. OSINGA, I.P. KEMA, B.F.A.M. VAN DER LAAN, R.P.F. DULLAART (Groningen, Netherlands) ........................................................................................................................................ 5153


Efficacy of Sunitinib in Patients with Renal Cell Carcinoma with Bone Metastases. B. PAULE, N. BRION (Creteil; Le Chesnay; Versailles, France) ........................................................................................................................................ 5165

Response and Safety of Sunitinib in a Heavily Pre-treated Metastatic Non-small Cell Lung Carcinoma Patient. R. TASSI, A. MUTO, S. RANGAN, A. VANNINI, L. POLITI, B. NERI (Florence, Italy) ................................................................................................................ 5169

Nuclear Expression of 14-3-3 Sigma Is Related to Prognosis in Patients with Esophageal Squamous Cell Carcinoma. H. OKUMURA, Y. KITA, N. YOKOMAKURA, Y. UCHIKADO, T. SETOYAMA, H. SAKURAI, I. OMOTO, M. MATSUMOTO, T. OWAKI, S. ISHIKAMI, S. NATSUGOE (Kagoshima, Japan) ................................................................................................................ 5175

Combined Chemoradiotherapy for Early Glottic Cancer in Clinical Practice in Japan: Analysis of 10 Institutions. Y. ITOH, N. HIRASAWA, S. NAGANAWA, S. ISHIHARA, K. SUZUKI, K. KOYAMA, T. MURAO, A. ASANO, Y. NOMOTO, Y. HORIKA, M. SASAOKA, Y. OBATA (Nagoya; Ichinomiya; Toyohashi; Yatomi; Hamamatsu; Tajimi; Tsu; Ise; Mie, Japan) ................................................................................................................ 5181


CA19.9 and CEA in Transitional Cell Carcinoma of the Bladder: Serological and Immunohistochemical Findings. A. HEGELE, V. MECKLENNBURG, Z. VARGA, P. OLBERT, R. HOFMANN, P. BARTH (Marburg; Siegenberg, Germany) ................................................................................................................ 5195

Ethynylestradiol Improves Prostate-specific Antigen Levels in Pretreated Castration-resistant Prostate Cancer Patients. K. IZUMI, Y. KADONO, T. SHIMA, H. KONAKA, A. MIZOKAMI, E. KOH, M. NAMIKI (Kanazawa, Japan) ................................................................................................................ 5201

A Rapid and Simple HPLC Assay for Quantification of Capecitabine for Drug Monitoring Purposes. A. FARKOUH, D. ETTLINGER, J. SCHUELLER, A. GEORGOPoulos, W. SCHEITHAUER, M. CZEJKA (Vienna, Austria) ................................................................................................................ 5207

Bevacizumab and Glioblastomas, a Single-Centre Experience: How Disease History and Characteristics May Affect Clinical Outcome. F. ZUSTOVICH, G. LOMBARDI, D. PASTORELLI, P. FARINA, L. FURINI, R. MANARA, M.D. PALMA, A. ROTILIO, O. NICOLETTO, V. ZAGONEL (Padova, Italy) ................................................................................................................ 5213

Contents continued on the preceding page
High-mobility Group B1 (HMGB1) and Receptor for Advanced Glycation End-products (RAGE) Expression in Canine Lymphoma. K.A. STERENCZAK, A.E. JOETZKE, S. WILLENBROCK, N. EBERLE, S. LANGE, C. JUNGHANSS, I. NOLTE, J. BULLERDIEK, D. SIMON, H.M. ESCOBAR (Hannover; Bremen; Rostock, Germany) .......................................................... 5043

Effects of the Synthetic Vasopressin Analog Desmopressin in a Mouse Model of Colon Cancer. G.V. RIPOLL, J. GARONA, G.A. HERMO, D.E. GOMEZ, D.F. ALONSO (Buenos Aires, Argentina) ................. 5049


Activation of the Serine/Threonine Protein Kinase Akt in Enteropancreatic Neuroendocrine Tumors. M. GHAYOURI, D. BOULWARE, A. NASIR, J. STROSBERG, L. KVOLS, D. COPPOLA (Tampa, FL, USA) .......................................................... 5063

Tumor-specific Cytotoxicity and Type of Cell Death Induced by Benzaldehyde. K. ARIYOSHI-KISHINO, K. HASHIMOTO, O. AMANO, J. SAITOHI, M. KOCHI, H. SAKAGAMI (Saitama; Chiba, Japan) .......... 5069

Aromatase Expression in Leptin-pretreated Human Breast Pre-adipocytes is Enhanced by Zeranol and Suppressed by (−)-Gossypol. S. ZHONG, W.-P. YE, P.-P. XU, E. FENG, H. LI, S.-H. LIN, J.-Y. LIU, C. MA, Y.C. LIN (Beijing, PR China; Columbus, OH, USA) .................. 5077

Investigation of Peroxiredoxin IV as a Calpain-regulated Pathway in Cancer. H. ROUMES, A. PIRES-ALVES, L. GONTHIER-MAURIN, E. DARGELOS, P. COTTIN (Talence, France) .................. 5085

Clinical Studies


Carbon Ion Radiotherapy for Treatment of Prostate Cancer and Subsequent Outcomes after Biochemical Failure. J. SHIMAZAKI, H. TSUJI, H. ISHIKAWA, T. OKADA, K. AKAKURA, H. SUZUKI, M. HARADA, H. TSUJI (Chiba; Yokohama, Japan) .............................. 5105

Oxaliplatin-induced Pancreatitis: A Case Series. W. BUTT, H. SAADATI, M.W. SAIF (Dayton, OH; New Haven, CT; New York, NY, USA) .................................................. 5113

A Mediastinal Somatic-type Germ Cell Tumor with Hepatic Metastasis Successfully Treated by Multiple Modalities. N. KOBASHI, T. KOZUMI, T. EGUCHI, A. HYOGOTANI, G. SAI TO, K. HAMANAKA, T. SHIINA, M. KURAI, R. KONDO, K. YOSHIDA, J. AMANO (Matsumoto, Japan) .................. 5117

Prognostic and Predictive Implications of EGFR Mutations, EGFR Copy Number and KRAS Mutations in Advanced Stage Lung Adenocarcinoma. L. BONANNO, M. SCHIAVON, G. NARDO, R. BERTORELLE, L. BONALDI, A. GALLIGIONI, S. INDRACCOLO, G. PASELLO, F. REA, A. FAVARETTO (Padua, Italy) .......... 5121


Contents continued on the preceding page